Xencor, Inc. is a biopharmaceutical company developing engineered antibodies for cancer and autoimmune disease treatment. The company has marketed therapies including Ultomiris for hemolytic uremic syndrome and myasthenia gravis, and Monjuvi for certain lymphomas, while maintaining a pipeline of experimental bispecific antibodies and other immunotherapies targeting various malignancies and inflammatory conditions. Headquartered in Pasadena, California, the company was founded in 1997.

entry readiness 24 · NOT READY · exit proximity 35

Value area 10.38–22.11 · 20% of 120d volume overhead · moderate overhead